'Sangsang Sangsang' Soars 184%... Retail Investors Flock to Boston Dynamics' 'Pick'
Boston Dynamics' Private Visit… Hwasin Precision Hits Fourth Consecutive Daily Limit Up [Featured Stock]
Closing price on June 5: 2,020 won
As of 9:36 a.m. on June 11, the stock hit its daily price limit of 5,750 won
[Edaily Reporter Kwon Oh-seok] Automotive parts manufacturer #Hwashin Precision is hitting its daily price limit for the fourth consecutive day. Buying momentum appears to be continuing following reports that Boston Dynamics, the robotics subsidiary of the Hyundai Motor Group, paid a private visit to Hwashin Precision. Hwasin Precision Engineering factory in Donam-dong, Yeongcheon, North Gyeongsang Province (Photo: Captured from Naver Street View) According to MP Doctor on the 11th, as of 9:36 a.m., Hwasin Precision is trading at the daily price limit of 5,750 won, up 29.80% from the previous trading day. Hwasin Precision has closed at the daily price limit for three consecutive days, from the 8th through the previous day. This surge in investor sentiment was sparked by a media report stating that Boston Dynamics engineers visited Hwasin Precision’s headquarters in Yeongcheon, North Gyeongsang Province, on the 5th to assess the possibility of sourcing parts for humanoid robots. In response, the Korea Exchange announced yesterday that it would designate Hwasin Precision as an “investment warning stock” effective today. For investment warning stocks, investors must pay 100% of the margin deposit when buying, and margin trading is prohibited. If the stock price continues to surge sharply after the designation, trading may be suspended.
The biggest bottleneck for AI servers is memory. As the KV cache—where large language models (LLMs) store past computations—accumulates, the required memory capacity increases exponentially. This prob…
Concerns about “tax risks” have been raised in some quarters of the financial investment, pharmaceutical, and biotech markets regarding Genosco, a subsidiary of OSCOTEC Inc.(039200)specializing in new…
As July began (June 29–July 3), the pharmaceutical and biotech industries turned their attention to Celltrion Pharm Inc.’s large-scale investment in production facilities and AriBio’s successful fundr…
